ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ESSA Pharma Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Total Equity
$124.6m
CAGR 3-Years
-14%
CAGR 5-Years
21%
CAGR 10-Years
51%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Total Equity
CA$19.4m
CAGR 3-Years
199%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Total Equity
-$19.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Equity
$388m
CAGR 3-Years
9%
CAGR 5-Years
26%
CAGR 10-Years
23%
Covalon Technologies Ltd
XTSX:COV
Total Equity
CA$21.7m
CAGR 3-Years
34%
CAGR 5-Years
16%
CAGR 10-Years
13%
Spectral Medical Inc
TSX:EDT
Total Equity
-CA$31.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Total Equity?
Total Equity
124.6m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Total Equity amounts to 124.6m USD.

What is ESSA Pharma Inc's Total Equity growth rate?
Total Equity CAGR 10Y
51%

Over the last year, the Total Equity growth was -14%. The average annual Total Equity growth rates for ESSA Pharma Inc have been -14% over the past three years , 21% over the past five years , and 51% over the past ten years .

Back to Top